Hyperuricemia and tumor lysis syndrome in children with non-Hodgkin's lymphoma and acute lymphoblastic leukemia

Simple item page
dc.contributor.buuauthorSevinir, Betül Berrin
dc.contributor.buuauthorDemirkaya, Metin
dc.contributor.buuauthorBaytan, Birol
dc.contributor.buuauthorGüneş, Adalet Meral
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatrik Hematoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatrik Onkoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1570-2021tr_TR
dc.contributor.scopusid6603199915tr_TR
dc.contributor.scopusid24331130000tr_TR
dc.contributor.scopusid6506622162tr_TR
dc.contributor.scopusid36087235900tr_TR
dc.date.accessioned2022-03-22T08:44:48Z
dc.date.available2022-03-22T08:44:48Z
dc.date.issued2011-03
dc.description.abstractObjective: This study aimed to examine the incidence, clinical characteristics, and outcome of hyperuricemia and tumor lysis syndrome (TLS) in children with non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Materials and Methods: This retrospective study included data from 327 patients (113 NHL and 214 ALL). Results: Hyperuricemia occurred in 26.5% and 12.6% of the patients with NHL and ALL, respectively. The corresponding figures for TLS were 15.9% and 0.47% (p=0.001). All hyperuricemic NHL patients had advanced disease and renal involvement was present in 53%. All hyperuricemic ALL patients had a leukocyte count >50,000 mm(3) at the time of diagnosis. Among the hyperuricemic NHL and ALL patients, 96.6% and 66.6% had LDH >= 500 UI/L, respectively. Treatment consisted of hydration and allopurinol; none of the patients received urate oxidase. Among the patients that developed TLS, 26.3% had laboratory TLS, 42.1% had grade I or II TLS, and 31.6% had grade III or IV TLS. Uric acid levels returned to normal after a mean period of 3.5+/-2.5 and 3.05+/-0.8 d in NHL and ALL groups, respectively. In all, 7% of the patients with hyperuricemia required hemodialysis. None of the patients died. Conclusion: In this series the factors associated with a high-risk for TLS were renal involvement in NHL and high leucocyte count in ALL. Management with allopurinol and hydration was effective in this group of patients with high tumor burden.en_US
dc.identifier.citationSevinir, B. vd. (2011). "Hyperuricemia and tumor lysis syndrome in children with non-Hodgkin's lymphoma and acute lymphoblastic leukemia". Turkish Journal of Hematology, 28(1), 52-59.tr_TR
dc.identifier.endpage59tr_TR
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1tr_TR
dc.identifier.pubmed27263942tr_TR
dc.identifier.scopus2-s2.0-79953209010tr_TR
dc.identifier.startpage52tr_TR
dc.identifier.urihttps://doi.org/10.5152/tjh.2011.06
dc.identifier.urihttps://jag.journalagent.com/tjh/pdfs/TJH_28_1_52_59.pdf
dc.identifier.urihttp://hdl.handle.net/11452/25262
dc.identifier.volume28tr_TR
dc.identifier.wos000288828600007tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.trdizinTrDizintr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherGalenos Yayıncılıktr_TR
dc.relation.journalTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHematologyen_US
dc.subjectNon-Hodgkin's lymphomaen_US
dc.subjectLeukemiaen_US
dc.subjectTumor lysis syndromeen_US
dc.subjectHyperuricemiaen_US
dc.subjectChildrenen_US
dc.subjectUrate oxidase rasburicaseen_US
dc.subjectClinical characteristicsen_US
dc.subjectPreventionen_US
dc.subjectManagementen_US
dc.subjectChildhooden_US
dc.subjectCanceren_US
dc.subject.emtreeAllopurinolen_US
dc.subject.emtreeLactate dehydrogenaseen_US
dc.subject.emtreeUrate oxidaseen_US
dc.subject.emtreeAcute lymphoblastic leukemiaen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHemodialysisen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHydrationen_US
dc.subject.emtreeHyperuricemiaen_US
dc.subject.emtreeIncidenceen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeKidney diseaseen_US
dc.subject.emtreeLaboratory diagnosisen_US
dc.subject.emtreeLactate dehydrogenase blood levelen_US
dc.subject.emtreeLeukocyte counten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNonhodgkin lymphomaen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSchool childen_US
dc.subject.emtreeTumor lysis syndromeen_US
dc.subject.scopusTumor Lysis Syndrome; Rasburicase; Hyperphosphatemiaen_US
dc.subject.wosHematologyen_US
dc.titleHyperuricemia and tumor lysis syndrome in children with non-Hodgkin's lymphoma and acute lymphoblastic leukemiaen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sevinir_vd_2011.pdf
Size:
132.1 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus
TrDizin